Regeneron Pharmaceuticals has entered a strategic collaboration with TriNetX to access de-identified electronic health records of approximately 300 million patients worldwide. This partnership allows Regeneron to link large-scale genomic and proteomic data with TriNetX's extensive phenotypic data network, expanding its database to accelerate drug discovery and development. The collaboration also aims to empower AI algorithms for future digital health solutions, enhancing capabilities for consumers, patients, and healthcare providers. Regeneron will invest up to $200 million in TriNetX as part of this deal, marking a significant step in integrating genomic data with real-world health information under strict privacy laws.
